The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
01-Apr-25
$153 million
Target:
Dipsol Chemicals
Acquiror:
Quaker Houghton
Advising Quaker Houghton, a global leader in industrial process fluids, on the acquisition of Dipsol Chemicals, a leading supplier of surface treatment and plating solutions and services primarily for automotive and other industrial applications
31-Mar-25
Pending
Undisclosed
Target:
Teijin Automotive Technologies – North America
Acquiror:
AURELIUS
Advising AURELIUS on the acquisition of Teijin Automotive Technologies (“TAT-NA”), the North American composites business being carved out from Japanese conglomerate Teijin Limited. TAT-NA is the leading North American player in advanced composite materials for the automotive, heavy truck, marine, and recreational vehicle sectors
10-Mar-25
Pending
$975 million
Target:
Avail Infrastructure Solutions
Acquiror:
nVent Electric plc
Advised Avail Infrastructure Solutions on the sale of its Electrical Products Group, a leading provider of specialized products and solutions designed to support industrial and electrical applications, to nVent Electric plc (NYSE: NVT), a global leader in electrical connection and protection solutions
04-Feb-25
Pending
$1.1 billion
Target:
PRISM Vision Group
Acquiror:
McKesson Corporation
Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader
10-Jan-25
Undisclosed
Target:
Ranger Design
Acquiror:
Clarience Technologies
Advised Ranger Design on its sale to Clarience Technologies, a portfolio company of Genstar Capital
13-Nov-24
Pending
Undisclosed
Target:
Centogene GmbH
Acquiror:
Charme Capital Partners
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
03-Oct-24
$1.1 billion
Target:
Tyman plc
Acquiror:
Quanex Building Products Corporation
Advised Tyman plc, a leading international supplier of fenestration components and access solutions to the construction industry, on the recommendation of a cash and share acquisition by Quanex, a global NYSE listed manufacturing company serving OEMs in the fenestration, cabinetry, solar, refrigeration and outdoor products markets
01-Oct-24
Undisclosed
Target:
Summit Electric Supply Co., Inc.
Acquiror:
Sonepar
Advised Summit Electric Supply Co., Inc, a founder and family-owned electrical distributor with operations across Arizona, Louisiana, New Mexico and Texas, on its sale to Sonepar USA Holdings, Inc., an independent, family-owned company with global market leadership in the B2B distribution of electrical products, solutions and related services
25-Sep-24
Pending
$115 million
Target:
Markforged Holding Corporation
Acquiror:
Nano Dimension Ltd.
Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Markforged, a developer of digital 3D printing solutions in metal and advanced composites
09-Sep-24
Undisclosed
Target:
Pixelligent Technologies
Acquiror:
Henkel Corporation
Advised Pixelligent Technologies, a developer and manufacturer of nanocrystal material used in consumer electronic devices, on a significant strategic investment from Henkel Corporation, a publicly traded (FWB: HEN) German multinational chemical and consumer goods company
28-Aug-24
Pending
Undisclosed
Target:
EthosEnergy
Acquiror:
One Equity Partners
Advised One Equity Partners, a middle market private equity firm, on the acquisition of EthosEnergy, a global independent turbine and rotating equipment service provider for power and process industries and for aerospace & defense markets
22-Aug-24
Undisclosed
Target:
PS
Acquiror:
Groupe ADP
Advised Groupe ADP, an international airport operator, on the acquisition of PS (formerly known as The Private Suite), an operator of private luxury terminals serving commercial flights, from TPG
03-Jul-24
Pending
$310 million
Target:
Desktop Metal, Inc.
Acquiror:
Nano Dimension Ltd.
Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Desktop Metal, a vertically integrated 3D printers, materials and software company and pioneer of several 3D printing technologies
01-Jul-24
Undisclosed
Target:
Medical Review Institute of America
Acquiror:
Parthenon Capital
Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital
08-May-24
$800 million
Target:
U.S. Acute Care Solutions
Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes
11-Jan-24
Undisclosed
Target:
ElectraMeccanica
Acquiror:
Xos
Advising ElectraMeccanica on its all-stock merger with Xos, a leading manufacturer of battery electric commercial vehicles
09-Jan-24
Pending
Undisclosed
Target:
RedBuilt LLC
Acquiror:
Hampton Lumber
Advising Hampton Lumber, a sustainable lumber producer, on the acquisition of RedBuilt LLC, a leader in custom engineered structural systems
04-Dec-23
$530 million
Target:
FW Murphy Production Controls
Acquiror:
Dover Corporation
Advised Genisys Controls LLC on the sale of FW Murphy Production Controls, an instrumentation company that provides advanced monitoring and protection solutions used in sophisticated process applications, to Dover Corporation, a diversified global manufacturer and solutions provider
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
19-Sep-23
$60 million
Target:
Williams Industrial Services Group
Acquiror:
EnergySolutions
Advised Williams Industrial Services Group, (NYSE: WLMS), a maintenance & construction services provider to the commercial nuclear power and heavy industry markets, on its Section 363 sale to EnergySolutions, a global provider of nuclear, energy and industrial services
21-Jun-23
Pending
Undisclosed
Target:
Jacobson/Gershwind Family
Acquiror:
MSC Industrial Direct Co.
Advising the Jacobson/Gershwind Family in connection with the elimination of MSC Industrial's Class B common stock, which included the conversion of each share of Class B common stock into the right to receive 1.225 shares of Class A common stock
01-Jun-23
Pending
Undisclosed
Target:
Interest in Joint Venture with CarepathRx Health System Solutions
Acquiror:
The Cigna Group
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
31-Mar-23
Pending
$306.6 - 319.2 million
Target:
HIS Company, Inc. (“Hisco”)
Acquiror:
Distribution Solutions Group, Inc.
Advising Hisco, a leading employee-owned distributor of specialty products serving high growth industrial technology applications, on its sale to Distribution Solutions Group, Inc. (Nasdaq: DSGR), a premier specialty distribution company providing high touch, value-added distribution solutions to the maintenance, repair & operations (MRO), original equipment manufacturer (OEM) and industrial technologies markets
07-Mar-23
Undisclosed
Target:
David Brown Santasalo
Acquiror:
Stellex Capital Management
Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies